Inhibikase Therapeutics (IKT) Retained Earnings (2020 - 2025)
Historic Retained Earnings for Inhibikase Therapeutics (IKT) over the last 6 years, with Q3 2025 value amounting to -$129.9 million.
- Inhibikase Therapeutics' Retained Earnings fell 5791.5% to -$129.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$129.9 million, marking a year-over-year decrease of 5791.5%. This contributed to the annual value of -$94.4 million for FY2024, which is 4113.54% down from last year.
- As of Q3 2025, Inhibikase Therapeutics' Retained Earnings stood at -$129.9 million, which was down 5791.5% from -$118.0 million recorded in Q2 2025.
- Inhibikase Therapeutics' 5-year Retained Earnings high stood at -$17.7 million for Q1 2021, and its period low was -$129.9 million during Q3 2025.
- Moreover, its 5-year median value for Retained Earnings was -$58.1 million (2023), whereas its average is -$62.0 million.
- In the last 5 years, Inhibikase Therapeutics' Retained Earnings plummeted by 29836.64% in 2021 and then plummeted by 3119.32% in 2024.
- Quarter analysis of 5 years shows Inhibikase Therapeutics' Retained Earnings stood at -$29.8 million in 2021, then crashed by 60.55% to -$47.9 million in 2022, then tumbled by 39.75% to -$66.9 million in 2023, then plummeted by 41.14% to -$94.4 million in 2024, then crashed by 37.62% to -$129.9 million in 2025.
- Its Retained Earnings was -$129.9 million in Q3 2025, compared to -$118.0 million in Q2 2025 and -$108.1 million in Q1 2025.